Cargando…

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial

BACKGROUND: How the immune microenvironment changes during neoadjuvant chemotherapy of primary breast cancer is not well understood. METHODS: We analyzed pre- and post-treatment samples from 60 patients using the NanoString PanCancer IO360™ assay to measure the expression of 750 immune-related genes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaotong, Warren, Sarah, Pelekanou, Vasiliki, Wali, Vikram, Cesano, Alessandra, Liu, Mingdong, Danaher, Patrick, Elliott, Nathane, Nahleh, Zeina A., Hayes, Daniel F., Hortobagyi, Gabriel N., Barlow, William E., Hatzis, Christos, Pusztai, Lajos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457012/ https://www.ncbi.nlm.nih.gov/pubmed/30967156 http://dx.doi.org/10.1186/s40425-019-0563-7

Ejemplares similares

Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
por: Fanucci, Kristina A., et al.
Publicado: (2023)

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
por: Nahleh, Z. A., et al.
Publicado: (2016)

Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade
por: Casadevall, David, et al.
Publicado: (2019)

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer
por: Wali, Vikram B., et al.
Publicado: (2019)

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
por: Speers, Corey W., et al.
Publicado: (2023)

Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221
por: Chen, Ciao-Sin, et al.
Publicado: (2023)

Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)
por: Bergqvist, Mattias, et al.
Publicado: (2023)

Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations
por: Patwardhan, Gauri A., et al.
Publicado: (2021)

Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer
por: Jiang, Tingting, et al.
Publicado: (2014)

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017)

Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017)

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers
por: Pelekanou, Vasiliki, et al.
Publicado: (2018)

Functional polymorphisms in cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

Friday 5 September, 0800–1000 Concurrent Session: Radiation Oncology Varian Prize
Publicado: (2014)

Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells
por: Marczyk, Michal, et al.
Publicado: (2020)

A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102
por: Gralow, Julie R., et al.
Publicado: (2013)

Characterization of DNA variants in the human kinome in breast cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
por: Jiang, Tingting, et al.
Publicado: (2016)

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes
por: Győrffy, Balázs, et al.
Publicado: (2018)

Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity
por: Shi, Weiwei, et al.
Publicado: (2018)

A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity
por: Danaher, Patrick, et al.
Publicado: (2019)

Correction to: A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity
por: Danaher, Patrick, et al.
Publicado: (2019)

Functional germline variants as potential co-oncogenes
por: Agarwal, Divyansh, et al.
Publicado: (2017)

Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers
por: O’Meara, Tess, et al.
Publicado: (2020)

Compte rendu de machine development 19.2.197o 0600 - 0800 high energy "q" measurements
por: Azzoni, G
Publicado: (1970)

Multigene prognostic tests in breast cancer: past, present, future
por: Győrffy, Balázs, et al.
Publicado: (2015)

A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients
por: Pongor, Lőrinc, et al.
Publicado: (2015)

Evaluation of zero counts to better understand the discrepancies between bulk and single-cell RNA-Seq platforms
por: Zyla, Joanna, et al.
Publicado: (2023)

Germline genetic variants in ABCB1, ABCC1, and ALDH1A1 and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer
por: Yao, Song, et al.
Publicado: (2013)

Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers
por: Li, Xiaotong, et al.
Publicado: (2021)

Stochastic extraction at 10 GeV/c: Machine development report (31 May 1979, 00.00-08.00)
por: Cappi, R, et al.
Publicado: (1979)

Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials
por: Nahleh, Zeina, et al.
Publicado: (2019)

Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy
por: Marcath, Lauren A., et al.
Publicado: (2021)

An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD
por: Bell-Brown, Ari, et al.
Publicado: (2022)

Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)
por: Louie, S G, et al.
Publicado: (2013)

Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
por: Boxley, Peter, et al.
Publicado: (2020)

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer
por: Marczyk, Michal, et al.
Publicado: (2022)

Run 115 - 21st October 1971 - 07.00 to 08.00h, Rings 1 and 2 - 26 GeV/c: Physics beams
por: Bryant, P J
Publicado: (1971)

Neoadjuvant treatment: the MD Anderson experience
por: Hortobagyi, GN
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_btr6hj05ov0lhunk5nh8ugir98